Amy Kruse

Amy Kruse, PhD is General Partner and Chief Investment Officer at Satori Neuro, a venture fund dedicated to transformative solutions in mental health, neurotechnology, and human flourishing. A seasoned neuroscientist, investor, and technology leader, Amy previously served as General Partner at Prime Movers Lab, focusing on human augmentation and longevity. She serves on the boards of nine portfolio companies across both funds, including Apollo Neuro, Attune Neurosciences, Gilgamesh Pharmaceuticals, Motif Neurotech, and Paradromics, and is an independent director of Kitware. Earlier, she was Chief Scientific Officer at Optios and Vice President and Chief Technology Officer at Cubic Global Defense, guiding advanced R&D programs. At DARPA, Amy pioneered performance-oriented neuroscience initiatives. A recognized thought leader, Amy serves on the External Oversight Committee of the NIH Blueprint MedTech program, advises teams pursuing ARPA-H translational programs, advises BrainMind and Capital Factory, and mentors for the OneMind Accelerator. She frequently contributes to DARPA, National Academies, and Defense Science Board advisory panels, and writes the newsletter New in Human Flourishing. Amy holds a BS and PhD in Neuroscience from the University of Illinois Urbana-Champaign, supported by a National Science Foundation Graduate Fellowship.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.